Skip to main content

Table 2 Clinical-pathological characteristics of 913 primary PCa patients by curative intent treatment

From: The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression

First line therapy

S/S + other

N (%)

RT/RT + HO

N (%)

P-value

Age (years)

  < 50

6 (1.6)

2 (0.4)

< 0.001*

  ≥ 50 and <60

107 (28)

28 (5.3)

  ≥ 60 and <75

266 (69.6)

401 (75.5)

  ≥ 75 and <80

2 (0.5)

86 (16.2)

  ≥ 80

1 (0.3)

14 (2.6)

Stage

 T1-T2

191 (50.1)

360 (68.2)

< 0.001*

 T3

186 (48.8)

156 (29.5)

 T4

4 (1.1)

12 (2.3)

Missing

1

3

Lymph nodes

 N0

322 (85.2)

514 (98.3)

< 0.001*

 N1

56 (14.8)

9 (1.7)

Missing

4

8

PSA (ng/ml)

  < 10

189 (56.4)

180 (34.3)

< 0.001*

 10–20

101 (30.2)

209 (39.9)

  ≥ 20

45 (13.4)

135 (25.8)

Missing

47

7

Gleason Score

 3–6

79 (22.1)

177 (35.9)

< 0.001*

 7

192 (53.6)

171 (34.7)

 8–10

87 (24.3)

145 (29.4)

Missing

24

38

First metastatic event

 Bone-only

30 (40.54)

20 (32.26)

0.158

 Loco/LN-only

28 (37.4)

24 (38.71)

 Visceral-only

1 (1.35)

6 (9.68)

 Multiple site

15 (20.27)

12 (19.35)

Total (N)

382

531

 
  1. S Surgery, RT Radiotherapy, HO Hormonal therapy; other: adjuvant therapy. *Significant value